News | 25 January 2013
MentiNova's oral drug would curb dyskenesia the involuntary movements caused by long-term use of levodopa, or L-Dopa, a drug taken by many of the 1 million people with the condition. Parkinson's disease, a degenerative disease of the central nervous ...
Click on the link to read the full article at MedCity News
(This link will open in a new window)